Patients’ own cells transformed into model for studying disease and developing potential treatment
Columbia University Medical Center (CUMC) researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss. The approach, the first of its kind, takes advantage of induced pluripotent stem (iPS) cell technology to transform skin cells into retinal cells, which are then used as a patient-specific model for disease study and preclinical testing.
Using this approach, researchers led by Stephen H. Tsang, MD, PhD, showed that a form of RP caused by mutations to the gene MFRP (membrane frizzled-related protein) disrupts the protein that gives retinal cells their structural integrity. They also showed that the effects of these mutations can be reversed with gene therapy. The approach could potentially be used to create personalized therapies for other forms of RP, as well as other genetic diseases. The paper was published recently in the online edition of Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy.
“The use of patient-specific cell lines for testing the efficacy of gene therapy to precisely correct a patient’s genetic deficiency provides yet another tool for advancing the field of personalized medicine,” said Dr. Tsang, the Laszlo Z. Bito Associate Professor of Ophthalmology and associate professor of pathology and cell biology.
The Latest on: Personalized Gene Therapy
[google_news title=”” keyword=”Personalized Gene Therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalized Gene Therapy
- Novel Gene Editing Tool Improves Immune Cell Activityon February 29, 2024 at 8:00 am
Jennifer Doudna and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in gene editing. The gene editing techn | Immunology ...
- Why Cell And Gene Therapy Design Processes Need More Efficient Quality Controlson February 29, 2024 at 3:00 am
Drugmakers must make the entire drug testing and quality control process as efficient and innovative as the drug discovery method itself.
- Form Bio’s AI Ensures Gene Therapies Pass Muster, with Ginkgo’s Helpon February 28, 2024 at 5:37 pm
Now, the company announces a partnership with Ginkgo Bioworks to bring their AI out of the computer and into production. The two companies are currently teaming up on gene therapy, however they may ...
- Multigene Assays Advance Genetic Testing in Breast Cancer, Drive Personalized Medicineon February 28, 2024 at 3:59 pm
Multigene assays allow for patients to receive personalized breast cancer ... between endocrine and chemoendocrine therapy for patients with an intermediate-risk of HR-positive breast cancer.
- Personalized Cancer Therapy Coming of Age: Clinical Highlights in 2009 and Future Directionson February 28, 2024 at 3:59 pm
Additional evaluations are needed to better define the clinical utility of gene signatures ... 2010 Future Medicine Ltd. Cite this: Personalized Cancer Therapy Coming of Age: Clinical Highlights ...
- Genetic studies shed light on hypertension risk but fall short of revealing new treatmentson February 27, 2024 at 9:29 pm
Genetic variant research in hypertension has identified numerous associations but is unlikely to yield new treatments, emphasizing the gap between scientific discovery and clinical application.
- Redefining Cell and Gene Therapy Navigationon February 26, 2024 at 4:00 pm
Charles River’s suite of cell and gene therapy solutions can support your drug’s entire lifecycle, from discovery to commercialization. We have supported the development of 11 FDA-approved cell and ...
- Poseida: New CEO, same passion for allogeneic therapieson February 26, 2024 at 9:12 am
CEO of Poseida Therapeutics, Kristin Yarema discusses her goals and why the firm is focused on allogeneic therapies.
- New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggleon February 23, 2024 at 8:01 am
Goodwin also worries about the cost. Vertex Pharmaceuticals ' gene therapy Casgevy lists for $2.2 million, while Bluebird Bio 's treatment Lyfgenia lists for $3.1 million. "I do have insurance ...
- Is a treatment for those at genetic risk of Alzheimer's on the horizon?on February 17, 2024 at 10:00 pm
A study in mice and nematodes has investigated a potential new therapeutic approach that could help people with the genetic variant that predisposes them to Alzheimer's disease.
via Bing News